Amgen (NASDAQ:AMGN – Get Free Report) had its price objective lifted by stock analysts at Wells Fargo & Company from $390.00 to $400.00 in a note issued to investors on Wednesday. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 2.40% from the stock’s current price. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen Company Profile(Get Free Report)Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California.